– Presentation with live audio webcast on Wednesday, April 22 at 1:30 PM ET, immediately followed by an interactive Q&A session –San Diego, California, April 15, 2020 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), a company (i) that has developed medical foods and medical devices in the ocular health marketplace and (ii) that is developing nutraceuticals that the Company believes will provide health benefits to consumers, announced today that Michael Favish, CEO of Guardion Health Sciences, will present at the April 2020 Virtual Investor Summit on Wednesday, April 22nd, 2020 at 1:30 PM Eastern Time.A live audio webcast of the presentation will be available in the News and Events section of the Company’s website (guardionhealth.com). Immediately following the presentation, management will participate in an interactive Q&A session with interested parties, allowing participants to type in questions and receive live responses.To schedule a one-on-one call with management, please contact the conference at info@virtualinvestorsummit.com and for more information, please visit www.virtualinvestorsummit.com.The Virtual Investor Summit is an online platform that offers both public and private companies, across multiple industries the ability to stay active and engaged with the investment community. Our inaugural summit on April 22-23, 2020 will feature company webcast presentations followed by a virtual, interactive Q&A session, allowing participants to type in questions and receive live responses. Interested participants also have the ability to request one-on-one calls with a featured company. For more information, please visit virtualinvestorsummit.com.About Guardion Health Sciences, Inc.Guardion is a specialty health sciences company (i) that has developed medical foods and medical devices in the ocular health marketplace and (ii) that is developing nutraceuticals that the Company believes will provide medicinal and health benefits to consumers. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov.Forward-Looking Statement DisclaimerWith the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the coronavirus (COVID-19) on the Company’s business and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Guardion Health Sciences, Inc.15150 Avenue of Science, Suite 200
San Diego, CA 92128
Phone: (858) 605-9055
Fax: (858) 630-5543
www.guardionhealth.comInvestor Relations Contact:
Jenene Thomas
JTC Team, LLC
Telephone: (833) 475-8247
E-Mail: jtc@jtcir.comPorter, LeVay & Rose, Inc.Michael Porter
Telephone: (212) 564-4700
E-mail: mike@plrinvest.com
Bay Street News